BioStock: Data backs up anti-tumour effect of Alligator’s lead asset

Interim phase II data suggests that Alligator Bioscience’s lead immunotherapy candidate mitazalimab can be an effective combination treatment for pancreatic cancer. Upholding those results, the company has presented even more data at recent conferences and published a paper in a renowned scientific journal.

Read the article at biostock.se:

Data backs up anti-tumour effect of Alligator’s lead asset - BioStock

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/